Financière de Tubize SA Ret. on assets
What is the Ret. on assets of Financière de Tubize SA?
The Ret. on assets of Financière de Tubize SA is -0.03%
What is the definition of Ret. on assets?
Return on assets indicates how profitable a company’s assets are in generating revenue. It is computed by dividing net income by average total assets.
ttm (trailing twelve months)
The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.
Ret. on assets of companies in the Health Care sector on EURONEXT compared to Financière de Tubize SA
What does Financière de Tubize SA do?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Companies with ret. on assets similar to Financière de Tubize SA
- Archon Minerals has Ret. on assets of -0.03%
- Grainger Plc has Ret. on assets of -0.03%
- Lakshmi Precision Screws has Ret. on assets of -0.03%
- FinTech Acquisition III has Ret. on assets of -0.03%
- FinTech Acquisition III has Ret. on assets of -0.03%
- Gati has Ret. on assets of -0.03%
- Financière de Tubize SA has Ret. on assets of -0.03%
- Seadrill Partners has Ret. on assets of -0.02%
- Seadrill Partners has Ret. on assets of -0.02%
- KCR Residential REIT plc has Ret. on assets of -0.02%
- Tyson Foods has Ret. on assets of -0.02%
- Gati has Ret. on assets of -0.02%
- Financiere Moncey SA has Ret. on assets of -0.02%